Business ❯ Healthcare ❯ Pharmaceuticals

Biotechnology

Acquisitions Clinical Trials Cell Therapies Pacira BioSciences Cancer Treatment Female Founders Engineering Solutions Drug Development Market Competition Neumora Therapeutics Alzheimer's Disease Company Development Merck & Co., Inc. Regeneron Pharmaceuticals Partnerships Mergers and Acquisitions Moderna Innovent Biologics Avalo Therapeutics Biotech Companies Biocon Ltd Cancer Treatments Oncology Cell Therapy mRNA Manufacturing Ultragenyx Pharmaceutical Obesity Treatments Biogen

AbbVie Agrees to Buy Apogee Therapeutics for $10.9 Billion

The acquisition secures an IL‑13 antibody with potential long‑interval dosing that positions AbbVie to replenish its immunology pipeline

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Roche to Acquire PathAI for $750 Million Upfront Plus Up to $300 Million in Milestones

Ultragenyx Hit With Securities Class Action Over Failed Phase III Trials

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Pfizer Sues Metsera and Novo Nordisk to Block Termination of $4.9 Billion Deal

BioCryst to Acquire Astria in $700 Million Cash-and-Stock Deal to Bolster HAE Portfolio

Moderna Cuts 10% of Global Workforce in Major Cost Overhaul

AbbVie to Acquire Capstan Therapeutics for $2.1 Billion to Boost In Vivo CAR-T Portfolio